What is the recommended dose of Cefdinir (Cefdinir) for a pediatric patient with Impetigo (Impetigo)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefdinir Dosing for Impetigo in Pediatric Patients

For impetigo in children, administer cefdinir 7 mg/kg every 12 hours (twice daily) for 10 days, up to a maximum total daily dose of 600 mg. 1

Dosing Specifics

The FDA-approved dosing for uncomplicated skin and skin structure infections (including impetigo) in pediatric patients aged 6 months through 12 years is:

  • 7 mg/kg every 12 hours for 10 days 1
  • Maximum daily dose: 600 mg (for children ≥43 kg) 1
  • Once-daily dosing has NOT been studied for skin infections and should not be used 1

Weight-Based Dosing Chart (using 125 mg/5 mL suspension)

  • 9 kg (20 lbs): 2.5 mL every 12 hours 1
  • 18 kg (40 lbs): 5 mL every 12 hours 1
  • 27 kg (60 lbs): 7.5 mL every 12 hours 1
  • 36 kg (80 lbs): 10 mL every 12 hours 1
  • ≥43 kg (95 lbs): 12 mL every 12 hours 1

Clinical Context and Evidence

While cefdinir is FDA-approved for skin infections, it is NOT the first-line agent for impetigo. 2 The American Academy of Pediatrics recommends topical mupirocin 2% ointment three times daily for 5 days as first-line therapy for localized impetigo, as it is equally or more effective than oral antibiotics with fewer side effects. 2

When oral antibiotics are indicated (extensive disease, multiple lesions, or failed topical therapy), cephalexin 25-50 mg/kg/day divided into 3-4 doses for 7 days is the preferred oral agent, not cefdinir. 2 Cephalexin provides excellent coverage against both Staphylococcus aureus and Streptococcus pyogenes, the primary pathogens in impetigo. 2

When to Consider Cefdinir

Cefdinir may be appropriate as an alternative oral agent when:

  • Patient cannot tolerate cephalexin 3
  • Twice-daily dosing is preferred for adherence over three or four times daily 1, 4
  • Penicillin allergy exists (non-Type I hypersensitivity) 3

Clinical trials demonstrate cefdinir 7 mg/kg twice daily achieves 99.4% microbiologic eradication and 98.3% clinical cure rates in pediatric skin infections, including impetigo. 4 The most common pathogens isolated were S. aureus and S. pyogenes, with excellent activity against both. 4

Administration Details

  • May be given without regard to meals 1
  • Suspension remains stable for 10 days after reconstitution at room temperature 1
  • Shake well before each dose 1

Adverse Effects

Diarrhea is the most common adverse event, occurring in approximately 8% of pediatric patients receiving cefdinir for skin infections. 4 This is slightly higher than cephalexin (4%), though the difference is generally well-tolerated. 4

Critical Pitfall to Avoid

Do NOT use once-daily dosing for skin infections. 1 While once-daily cefdinir is effective for respiratory infections, it has not been studied for skin infections and the FDA label explicitly requires twice-daily administration for this indication. 1

Renal Dosing Adjustment

For pediatric patients with creatinine clearance <30 mL/min/1.73 m², reduce dose to 7 mg/kg (up to 300 mg) once daily. 1 For patients on hemodialysis, give 7 mg/kg every other day, with an additional dose after each dialysis session. 1

References

Guideline

Impetigo Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.